Lumos Pharma Stock EBITDA
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos |
Lumos Pharma Company EBITDA Analysis
Lumos Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Lumos Pharma EBITDA | (36.57 M) |
Most of Lumos Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Lumos Pharma reported earnings before interest,tax, depreciation and amortization of (36.57 Million). This is 104.17% lower than that of the Biotechnology sector and 136.51% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.94% higher than that of the company.
Lumos EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in ebitda category among its peers.
Lumos Fundamentals
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Shares Owned By Insiders | 32.69 % | |||
| Shares Owned By Institutions | 24.27 % | |||
| Number Of Shares Shorted | 54.33 K | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X | |||
| Price To Sales | 17.02 X | |||
| Revenue | 2.05 M | |||
| Gross Profit | 1.52 M | |||
| EBITDA | (36.57 M) | |||
| Net Income | (34.03 M) | |||
| Cash And Equivalents | 79.51 M | |||
| Cash Per Share | 9.49 X | |||
| Total Debt | 585 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.59 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (31.09 M) | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (4.28) X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 4.25 | |||
| Number Of Employees | 30 | |||
| Beta | 0.33 | |||
| Market Capitalization | 37.54 M | |||
| Total Asset | 40.64 M | |||
| Retained Earnings | (161.52 M) | |||
| Working Capital | 33.01 M | |||
| Current Asset | 115.78 M | |||
| Current Liabilities | 14.4 M | |||
| Net Asset | 40.64 M |
Pair Trading with Lumos Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HP could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HP when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HP - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HP Inc to buy it.
The correlation of HP is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HP moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HP Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HP can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |